This company is no longer in business. Investors can get details about any potential exits or failures here.

NowRx

NowRx

Early Stage

Technology-driven, on-demand pharmacy providing free, same-day delivery

Technology-driven, on-demand pharmacy providing free, same-day delivery

Overview

Funding data not publicly available
Platform

SeedInvest

Start Date

01/18/2018

Close Date

06/30/2018

Min. Goal
$450,000
Max. Goal
$7,000,000
Min. Investment

$1,000

Security Type

Equity - Preferred

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$2.00

Pre-Money Valuation

$20,000,000

Year Founded

2015

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

Mountain View, California

NowRx, with a valuation of $20 million, is raising funds on SeedInvest through Reg A+ crowdfunding. It is a pharmacy delivery solution that uses advanced technology to provide free same-day delivery for all prescription needs. The on-demand delivery model of NowRx offers convenience, higher worker productivity, and superior customer experience. NowRx has filled more than 16,000 prescriptions and served over 2,700 customers since June 2017, and generated revenues of approximately $1 million. Cary Breese and Sumeet Shoekand founded NowRx in 2015. The current crowdfunding campaign has a minimum target of $450,000 and a maximum target of $7,000,000. The campaign proceeds will be used for building the software, research and development, marketing, and expansion of services.

Balance Sheet

Cash and Cash Equivalents

$391,723

Accounts and Notes Receivable

$172,543

Property, Plant and Equipment (PP&E)

$136,446

Total Assets

$954,831

Accounts Payable & Accrued Liabilities

$105,609

Long Term Debt

$2,072,731

Total Liabilities

$2,188,261

Total Stockholders' Equity

$-1,233,430

Total Liabilities and Equity

$954,831

Statement of Comprehensive Income Information

Total Revenues

$994,588

Costs & Expenses Applicable to Rev

$823,073

Depreciation and Amortization

$2,677

Net Income

$-364,505

Earnings Per Share - Basic

$-0.09

Earnings Per Share - Diluted

$-0.09

Auditor: Fruci & Associates II, PLLC
Financials as of: 01/18/2018
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
NowRx 05/19/2022 SeedInvest $275,000,000 $30,006,323 Equity - Preferred Funded RegA+
NowRx 10/04/2021 SeedInvest $275,000,000 $3,635,310 Equity - Preferred Funded Test the Waters / RegA+
NowRx 06/18/2020 SeedInvest $65,000,000 $20,002,878 Equity - Preferred Funded RegA+
NowRx 06/29/2018 SeedInvest $20,000,000 - Equity - Preferred Funded RegA+
NowRx 07/18/2017 SeedInvest $6,000,000 - Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Analyst Report Analyst Report Methodology Article

Summary

At time of publication, May 21, NowRX had raised $2.2M surpassing its $450K minimum

Next Section: Problem

Problem

We’ve all been there. You get sick and go to the doctor, who then tells you to go and get a prescription for whatever ailment you are currently dealing with. Nothing quite like going to a CVS on the other side of town to hang out for 45 minutes while they fill your order, am I right?

Not only is the process friction filled from a customer experience standpoint, but is also a costly business to run with lots of overhead, which only helps to drive up the cost of healthcare services. In an age of on-demand everything, our pharmaceutical purchase experience should be no different.

The $260B retail RX market is in need of innovation that will help to mirror the experience customers have come to demand from e-commerce companies like Amazon. As crazy as that may sound, more-and-more C-Suite individuals from across highly regulated and slow moving industries like financial services and healthcare are speaking out on the impact that Amazon is having on customer experience demands. Customers have come to expect frictionless purchasing experiences, vast selection, and free, quick delivery no matter what the product is, be checks for a new bank account, or medicine for your sore throat.

The pharmacy industry has also been slow to innovate on ways to improve medication adherence and mistakes in medical dispensing. If we want better healthcare outcomes we will need to see more solutions like a PillPack finding unique and innovative solutions to improve both error rates and adherence.

Next Section: Solution

Solution

NowRX is creating an on-demand pharmacy delivery system that is going to create cost efficiencies for the healthcare world, better service for the customer, and improved adherence to pharmaceuticals.

The solution involves creating automated drug dispensary centers that are completely automated from acceptance of the prescription to fulfillment, with free same day delivery. Customers can order through their phone via app or text to mimic services like Uber. This is enabled by the pharmacy management system the team has built on the backend to ensure accurate, compliant and friendly communications with customers. And for just $5 customers can get their medicine delivered to their door in just 1 hour.

If you think about the cost efficiencies this creates, the team touts an ability to service a geographic radius that is 5X that of a traditional drug store with its NowRX delivery service. Instead of having to build 30 or 40 CVS drug stores in a city to service customers, NowRX can build one. That type of efficiency, cost savings and improvement on customer experience is why they have been able to close agreements with McKesson, Express Scripts, Caremark and OptumRx.

It is also that efficiency that enables free same day delivery while still leaving enough margin for the company to be profitable. The fulfillment centers are extremely lean in terms of staff but the staff that is present can focus less on the manual process of finding drugs and more on ensuring quality of experience. The team is also building out its data analytics to determine ways in the future to help customers better adhere to their pharmaceutical regimens.

Once again the team is finding ways to provide value add to the healthcare system at large, which means many stakeholders, from the insurers, to the pharmaceutical organizations have a stake in seeing a business like this succeed.

Next Section: Why We Like it

Why We Like it

  1. Massive market opportunity: NowRX is innovating in the $260B retail RX market that has been dominated by old, stodgy organizations like CVS and Walgreens to date. Though there are a handful of startup competitors such as Alto, PillPack, and Caps ule innovating in this space too, there is more than enough room for several companies to win out in this space and have successful exits or IPOs.
  2. Market traction: To date, the team has only rolled out 1 center in San Francisco. With this one center the team most recently reported that ARR is at $4.3M. And the team expects each center to drive $10M in annual revenue when at full tilt. In addition during 2017, the company experienced 236% revenue growth, and since launch has serviced 5,900 customers and fulfilled 28K prescriptions.
    1. This team has shown an ability to execute on the vision successfully and with no red flags to date in the SF market.
  3. Demand for healthcare transformation: Increasingly, insurance companies which continue to raise the cost of healthcare are demanding better measures of performance to justify cost of treatments, drugs, etc. NowRX fits in perfectly with this vision because it is both more affordable, drives better adherence to drugs, and thus improves outcomes. This is something that will likely become industry standard in the years to come. That gives NowRX a strong market position early in the game.
  4. Ripe market for acquisition: Recently it was announced that PillPack is in talks with Amazon to be acquired for somewhere in the neighborhood of $1B as the organization looks to provide a uniquely differentiated offering for customers in comparison to traditional pharmacies. Amazon was also reportedly pursuing the company too as the battle to own the “e-commerce” pharmacy starts to heat up. Now RX could see some intriguing acquisition offerings in the near future.

Next Section: Other

The Leadership

Cary Brees: Co-Founder & CEO

Cary Breese is an electrical engineer who has spent the past 15+ years turning around businesses and driving huge returns for investors including at a struggling insurance business. He also led a tech company called GenieDB in a complete product and business model redirect that ended in an acquisition from a large multinational telecom organization. He also helped found a successful $50M VC fund all before starting NowRx. Needless to say Cary is extremely seasoned in building businesses, managing tight balance sheets and successfully returning investors money.

Sumeet Shoekand: Co-Founder & CTO

Sumeet Shoekand has a great deal of experience in managing product development with past management experience as Tech Manager at Experian and VP of Tech at X1 Technologies, an enterprise software company. He also has experience working with Cary, because he was the CTO at GenieDB during the turnaround efforts, which included a full product redirect.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
NowRx on SeedInvest 2018
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $20,000,000
Price per Share: $2.00

Follow company

Follow NowRx on SeedInvest 2018

Buy NowRx's Deal Report

Warning: according to the close date for this deal, NowRx may no longer be accepting investments.

NowRx Deal Report

Get KingsCrowd’s comprehensive report on NowRx including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NowRx is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the NowRx deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge